Clinical Trial

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment option for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-08
notable Primary completion pushed: 2025-12 -> 2027-01-01 2026-08-08
Trial Details
NCT Number NCT05713838
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Esophagus Adenocarcinoma
Enrollment 32 participants
Start Date 2023-08-28
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07